Inventor · disambiguated record
Hanspeter Rottensteiner
Also filed as: ROTTENSTEINER HANSPETER
34 granted patents·27 pending applications·119 citations·filing 2009–2024
96Inventor score
Top patents by PatentIndex Score
61 records- 0194US8623612B2Method for testing treatment of ADAMTS13 deficiencyBAXTER INT·Filed 2013·Granted Jan 7, 2014·10 cites·21 claims
- 0293US9731024B2Nucleophilic catalysts for oxime linkageBAXALTA INC·Filed 2014·Granted Aug 15, 2017·9 cites·15 claims
- 0393US9110085B2Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factorBAXTER INT·Filed 2013·Granted Aug 18, 2015·8 cites·17 claims
- 0492US10209263B2Methods of measuring adamts 13 activityBAXALTA INC·Filed 2016·Granted Feb 19, 2019·5 cites·32 claims
- 0592US10189888B2Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia ABAXALTA INC·Filed 2016·Granted Jan 29, 2019·6 cites·38 claims
- 0691US8809501B2Nucleophilic catalysts for oxime linkageSIEKMANN JUERGEN·Filed 2012·Granted Aug 19, 2014·7 cites·34 claims
- 0790US10576160B2Nucleophilic catalysts for oxime linkageBAXALTA INC·Filed 2017·Granted Mar 3, 2020·3 cites·15 claims
- 0890US8642737B2Nucleophilic catalysts for oxime linkageSIEKMANN JUERGEN·Filed 2011·Granted Feb 4, 2014·12 cites·66 claims
- 0989US10414793B2Nucleophilic catalysts for oxime linkageBAXALTA INC·Filed 2016·Granted Sep 17, 2019·4 cites·52 claims
- 1089US9492555B2Nucleophilic catalysts for oxime linkageBAXALTA INC·Filed 2013·Granted Nov 15, 2016·7 cites·7 claims
- 1188US9488651B2Methods of measuring ADAMTS 13 activityBAXALTA INC·Filed 2014·Granted Nov 8, 2016·3 cites·18 claims
- 1287US8637640B2Blood coagulation protein conjugatesSIEKMANN JUERGEN·Filed 2010·Granted Jan 28, 2014·9 cites·9 claims
- 1387US2024335549A1Therapeutic proteins with increased half-life and methods of preparing sameBAXALTA INC·Filed 2024·Application pending·0 cites
- 1486US8945897B2Materials and methods for conjugating a water soluble fatty acid derivative to a proteinSIEKMANN JUERGEN·Filed 2011·Granted Feb 3, 2015·15 cites·37 claims
- 1586US8415114B2Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereofVARADI KATALIN·Filed 2009·Granted Apr 9, 2013·8 cites·18 claims
- 1685US10842853B2Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia BBAXALTA INC·Filed 2018·Granted Nov 24, 2020·2 cites·25 claims
- 1785US10350301B2Blood coagulation protein conjugatesBAXALTA INC·Filed 2016·Granted Jul 16, 2019·4 cites·35 claims
- 1882US11040109B2Blood coagulation protein conjugatesBAXALTA INC·Filed 2019·Granted Jun 22, 2021·1 cites·29 claims
- 1980US9795683B2Glycopolysialylation of non-blood coagulation proteinsJAIN SANJAY·Filed 2010·Granted Oct 24, 2017·3 cites·11 claims
- 2080US2022175939A1Therapeutic proteins with increased half-life and methods of preparing sameBAXALTA INC·Filed 2022·Application pending·0 cites
- 2176US10189889B2Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia ABAXALTA INC·Filed 2016·Granted Jan 29, 2019·2 cites·10 claims
- 2275US10900979B2Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)Baxalta GmbH·Filed 2019·Granted Jan 26, 2021·0 cites·23 claims
- 2374US2022213172A1Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia aTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 2473US11254731B2Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia ATAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Feb 22, 2022·0 cites·10 claims
- 2573US2021106691A1Therapeutic proteins with increased half-life and methods of preparing sameBAXALTA INC·Filed 2020·Application pending·0 cites
- 2672US11779635B2Subcutaneous administration of ADAMTS13TAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Oct 10, 2023·0 cites·17 claims
- 2772US2023211017A1Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia aTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 2870US11492388B2Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia ATAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Nov 8, 2022·0 cites·19 claims
- 2970US2020017543A1Nucleophilic catalysts for oxime linkageBAXALTA INC·Filed 2019·Application pending·0 cites
- 3070US2024100128A1Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expressionTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 3170US2025043310A1Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expressionTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 3268US11564992B2Nucleophilic catalysts for oxime linkageTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jan 31, 2023·0 cites·19 claims
- 3368US9611467B2Subcutaneous administration of ADAMTS13BAXALTA INC·Filed 2014·Granted Apr 4, 2017·1 cites·22 claims
- 3468US2010099616A1Modified blood factors comprising a low degree of water soluble polymerBAXTER INT·Filed 2009·Application pending·0 cites
- 3567US11999798B2Anti-factor IX padua antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Jun 4, 2024·0 cites·20 claims
- 3667US11707536B2Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia ATAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jul 25, 2023·0 cites·17 claims
- 3765US2019142958A1Therapeutic proteins with increased half-life and methods of preparing sameBAXALTA INC·Filed 2018·Application pending·0 cites
- 3865US2018318432A1Therapeutic proteins with increased half-life and methods of preparing sameBAXALTA INC·Filed 2018·Application pending·0 cites
- 3963US11596671B2Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expressionTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Mar 7, 2023·0 cites·16 claims
- 4063US11185575B2Subcutaneous administration of ADAMTS13TAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Nov 30, 2021·0 cites·30 claims
- 4163US10772968B2Glycopolysialylation of non-blood coagulation proteinsLIPOXEN TECH LIMITED·Filed 2017·Granted Sep 15, 2020·0 cites·2 claims
- 4263US2021128701A1Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarctionBAXALTA INC·Filed 2019·Application pending·0 cites
- 4362US2021128700A1Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia bBAXALTA INC·Filed 2020·Application pending·0 cites
- 4462US2019160178A1Modified blood factors comprising a low degree of water soluble polymerBAXALTA INC·Filed 2018·Application pending·0 cites
- 4560US2012329127A1Therapeutic proteins with increased half-life and methods of preparing sameSIEKMANN JUERGEN·Filed 2012·Application pending·0 cites
- 4660US2024269241A1Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expressionTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 4759US2024390517A1Aav8 capsid variants with enhanced liver targetingTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 4857US2014107320A1Blood coagulation protein conjugatesBAXTER HEALTHCARE SA·Filed 2013·Application pending·0 cites
- 4956US10413600B2Subcutaneous administration of ADAMTS13BAXALTA INC·Filed 2017·Granted Sep 17, 2019·0 cites·30 claims
- 5056US2012076749A1Modified Blood Factors Comprising a Low Degree of Water Soluble PolymerTURECEK PETER·Filed 2011·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hanspeter Rottensteiner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →